Evidence map›Paper›PMID 34684801›Full record

ArticleMolecules (Basel, Switzerland)2021

A Promiscuous Halogenase for the Derivatization of Flavonoids.

Dominik Kolling, Marc Stierhof, Constanze Lasch, Maksym Myronovskyi, Andriy Luzhetskyy

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecules (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.4field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Synthetic and systems biotechnology · 2026
    Review
  2. Article
  3. Review
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Dominik KollingDepartment of Pharmaceutical Biotechnology, Saarland University, 66123 Saarbruecken, Germany.
Marc StierhofDepartment of Pharmaceutical Biotechnology, Saarland University, 66123 Saarbruecken, Germany.ORCID 0000-0003-2201-7420
Constanze LaschDepartment of Pharmaceutical Biotechnology, Saarland University, 66123 Saarbruecken, Germany.
Maksym MyronovskyiDepartment of Pharmaceutical Biotechnology, Saarland University, 66123 Saarbruecken, Germany.
Andriy LuzhetskyyDepartment of Pharmaceutical Biotechnology, Saarland University, 66123 Saarbruecken, Germany.
Saarland University · DEHelmholtz Institute for Pharmaceutical Research Saarland · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Halogenation often improves the bioactive properties of natural products and is used in pharmaceutical research for the generation of new potential drug leads. High regio- and stereospecificity, simple reaction conditions and straightforward downstream processing are the main advantages of halogenation using enzymatic biocatalysts compared to chemical synthetic approaches. The identification of new promiscuous halogenases for the modification of various natural products is of great interest in modern drug discovery. In this paper, we report the identification of a new promiscuous FAD-dependent halogenase, DklH, from

Indexed as

HalogenationBacterial ProteinsBiocatalysisDrug DiscoveryFlavonoidsFrankiaGenes, BacterialMolecular Docking SimulationOxidoreductasesRecombinant ProteinsSubstrate SpecificityBacterial ProteinschrysinFlavonoidsOxidoreductasesRecombinant Proteinstryptophan halogenaseflavonoidFrankia alnihalogenaseheterologous expressionStreptomyces albus Del14

Identifiers

PMID34684801
PMCPMC8539768
OpenAlexW3205641692

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.